• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Bose Launches First FDA-Cleared DTC Hearing Aids

Share:

May 14, 2021

What You Should Know:

– Bose is entering the digital health market launch of Bose SoundControl Hearing Aids – the first FDA-cleared, direct-to-consumer hearing aid.

– Weighing 3 grams each, the new SoundControl™ Hearing Aids are developed for adults with perceived mild to moderate hearing loss. Eight batteries are included in the total, and one lasts up to four days when used 14 hours daily. They can be replaced wherever hearing aid batteries are sold and easily changed via a durable door on the exterior.

– Paired with the revolutionary Bose Hear app, users can fit, program, and control a SoundControl Hearing Aid for clinically proven, audiologist-quality results — without a doctor visit, hearing test, or prescription. And they can make setting adjustments themselves, in real-time and real-world environments, without assistance from a healthcare professional.

Clinical Study Outcomes/Results

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

In a clinical study with researchers at Northwestern University, Bose CustomTune technology yielded results that were as good if not better than those achieved by traditional prescription-fitting methods used by audiologists. The study’s participants were split into two groups with similar levels of hearing loss. One group used Bose CustomTune technology to self-tune a device, the other had the same device fit and tuned by an audiologist. Participants using Bose CustomTune technology reported being more satisfied with their sound quality than those whose devices were tuned by hearing health professionals.

Pricing & Availability

SoundControl Hearing Aids come with a 90-day risk-free trial, dedicated product support, and are available at a fraction of the cost of most conventional hearing aids. They will be sold directly from Bose for $849.95 starting May 18th in five states: Massachusetts, Montana, North Carolina, South Carolina, and Texas — with nationwide availability to follow.

Source: Hitconsultant

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Cadence Announces the Acquisition of ARC Group Worldwide’s Florida LocationCadence Announces the Acquisition of ARC Group Worldwide’s Florida Location
  • Accolade Acquires MD Insider for Machine Learning Physician PerformanceAccolade Acquires MD Insider for Machine Learning Physician Performance
  • Education, Culture Key to Artificial Intelligence in HealthcareEducation, Culture Key to Artificial Intelligence in Healthcare
  • Abbott Receives FDA Approval for World’s First Dual Chamber Leadless PacemakerAbbott Receives FDA Approval for World’s First Dual Chamber Leadless Pacemaker
  • BioLife Solutions Closes Acquisition of SciSafe, a High-Growth Biostorage Service Provider to the Cell and Gene Therapy IndustryBioLife Solutions Closes Acquisition of SciSafe, a High-Growth Biostorage Service Provider to the Cell and Gene Therapy Industry
  • Healthcare Interoperability Leader ELLKAY Acquires X-LinkHealthcare Interoperability Leader ELLKAY Acquires X-Link
  • XPhyto Signs Transformative Acquisition Agreement with 3a-Diagnostics, to Enter Hi-Tech Biosensor Market and Expand Its Diagnostic Product PortfolioXPhyto Signs Transformative Acquisition Agreement with 3a-Diagnostics, to Enter Hi-Tech Biosensor Market and Expand Its Diagnostic Product Portfolio
  • Liva Healthcare and Amgen Partner to Improve Access to Cardiac RehabilitationLiva Healthcare and Amgen Partner to Improve Access to Cardiac Rehabilitation

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications